Multiple interactive factors in hepatocarcinogenesis.

[1]  T. Shibata,et al.  Comprehensive genome sequencing of the liver cancer genome. , 2013, Cancer Letters.

[2]  Kristen Jepsen,et al.  Identification of Liver Cancer Progenitors Whose Malignant Progression Depends on Autocrine IL-6 Signaling , 2013, Cell.

[3]  I. Ng,et al.  Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma. , 2013, Cancer letters.

[4]  Tong Wu,et al.  Hedgehog signaling pathway regulates autophagy in human hepatocellular carcinoma cells , 2013, Hepatology.

[5]  F. Izzo,et al.  Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. , 2013, Genomics.

[6]  L. Tang,et al.  Cyclin G1 Expands Liver Tumor-Initiating Cells by Sox2 Induction via Akt/mTOR Signaling , 2013, Molecular Cancer Therapeutics.

[7]  Jing-jing Hu,et al.  Expression of intercellular adhesion molecule 1 by hepatocellular carcinoma stem cells and circulating tumor cells. , 2013, Gastroenterology.

[8]  Wei Zhao,et al.  1B50-1, a mAb raised against recurrent tumor cells, targets liver tumor-initiating cells by binding to the calcium channel α2δ1 subunit. , 2013, Cancer cell.

[9]  C. Heeschen,et al.  Standing out from the crowd: cancer stem cells in hepatocellular carcinoma. , 2013, Cancer cell.

[10]  Kostas Nikolaou,et al.  Molecular Pathways: The Complex Roles of Inflammation Pathways in the Development and Treatment of Liver Cancer , 2013, Clinical Cancer Research.

[11]  M. Ronaghi,et al.  Deep sequencing of the hepatitis B virus in hepatocellular carcinoma patients reveals enriched integration events, structural alterations and sequence variations. , 2013, Carcinogenesis.

[12]  Yoshiyuki Suzuki,et al.  Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C , 2013, Hepatology.

[13]  U. Nöthlings,et al.  Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort , 2013, International journal of cancer.

[14]  W. Koh,et al.  Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study , 2013, British Journal of Cancer.

[15]  Qiang Ding,et al.  Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus–related hepatocellular carcinoma , 2012, Nature Genetics.

[16]  J. Llovet,et al.  Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. , 2012, Gastroenterology.

[17]  T. Han,et al.  Hepatic transforming growth factor beta gives rise to tumor‐initiating cells and promotes liver cancer development , 2012, Hepatology.

[18]  L. Fabris,et al.  Notch signaling in hepatocellular carcinoma: guilty in association! , 2012, Gastroenterology.

[19]  E. Wagner,et al.  Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin , 2012, Nature Cell Biology.

[20]  N. Kato,et al.  Type 2 diabetes and hepatocellular carcinoma: A case–control study in patients with chronic hepatitis B , 2012, International journal of cancer.

[21]  Boping Zhou,et al.  Exome sequencing of hepatitis B virus–associated hepatocellular carcinoma , 2012, Nature Genetics.

[22]  Hans Clevers,et al.  Lineage Tracing Reveals Lgr5+ Stem Cell Activity in Mouse Intestinal Adenomas , 2012, Science.

[23]  Hong-Yang Wang,et al.  p28(GANK) prevents degradation of Oct4 and promotes expansion of tumor-initiating cells in hepatocarcinogenesis. , 2012, Gastroenterology.

[24]  Keith A. Boroevich,et al.  Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators , 2012, Nature Genetics.

[25]  Angela M. Liu,et al.  Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma , 2012, Nature Genetics.

[26]  S. Imbeaud,et al.  Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma , 2012, Nature Genetics.

[27]  Sean J Morrison,et al.  Cancer stem cells: impact, heterogeneity, and uncertainty. , 2012, Cancer cell.

[28]  M. Karin,et al.  Obesity, inflammation, and liver cancer. , 2012, Journal of hepatology.

[29]  Z. Herceg,et al.  From hepatitis to hepatocellular carcinoma: a proposed model for cross-talk between inflammation and epigenetic mechanisms , 2012, Genome Medicine.

[30]  Thomas D. Wu,et al.  The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. , 2012, Genome research.

[31]  Ze-Guang Han,et al.  DLK1 as a Potential Target against Cancer Stem/Progenitor Cells of Hepatocellular Carcinoma , 2012, Molecular Cancer Therapeutics.

[32]  L. Tang,et al.  Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in 3,5‐diethoxycarbonyl‐1,4‐dihydrocollidine‐treated HBx transgenic mice , 2012, Hepatology.

[33]  P. Sham,et al.  Genome-Wide Association Study of Hepatocellular Carcinoma in Southern Chinese Patients with Chronic Hepatitis B Virus Infection , 2011, PloS one.

[34]  W. Guo,et al.  Genome‐wide copy number analyses identified novel cancer genes in hepatocellular carcinoma , 2011, Hepatology.

[35]  T. Han,et al.  Gankyrin‐mediated dedifferentiation facilitates the tumorigenicity of rat hepatocytes and hepatoma cells , 2011, Hepatology.

[36]  P. Fortina,et al.  RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage. , 2011, Gastroenterology.

[37]  W. Ding,et al.  c‐Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma , 2011, Hepatology.

[38]  Michael A Choti,et al.  Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma , 2011, Nature Genetics.

[39]  C. Verslype,et al.  Molecular classification of hepatocellular carcinoma anno 2011. , 2011, European journal of cancer.

[40]  Jun Yu,et al.  Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives β-catenin/T cell factor-dependent hepatocarcinogenesis. , 2011, The Journal of clinical investigation.

[41]  I. Ng,et al.  CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. , 2011, Cell stem cell.

[42]  S. Mikhail,et al.  Liver Cancer Stem Cells , 2011, International journal of hepatology.

[43]  T. Han,et al.  Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. , 2011, Cancer cell.

[44]  L. Timchenko,et al.  Intracellular signaling and hepatocellular carcinoma. , 2011, Seminars in cancer biology.

[45]  Ming Yao,et al.  Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization , 2011, Hepatology.

[46]  I. Ng,et al.  Lupeol targets liver tumor‐initiating cells through phosphatase and tensin homolog modulation , 2011, Hepatology.

[47]  Kun Wu,et al.  Hepatocyte nuclear factor 4 alpha suppresses the development of hepatocellular carcinoma. , 2010, Cancer research.

[48]  K. Mimori,et al.  CD13 is a therapeutic target in human liver cancer stem cells. , 2010, The Journal of clinical investigation.

[49]  Sucha Singh,et al.  Conditional β‐catenin loss in mice promotes chemical hepatocarcinogenesis: Role of oxidative stress and platelet‐derived growth factor receptor α/phosphoinositide 3‐kinase signaling , 2010, Hepatology.

[50]  Fuchu He,et al.  Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers , 2010, Nature Genetics.

[51]  Y. Hung,et al.  Androgen Receptor Promotes Hepatitis B Virus–Induced Hepatocarcinogenesis Through Modulation of Hepatitis B Virus RNA Transcription , 2010, Science Translational Medicine.

[52]  S. Qiu,et al.  High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma , 2010, Gut.

[53]  S. Friedman,et al.  Obesity, inflammatory signaling, and hepatocellular carcinoma-an enlarging link. , 2010, Cancer cell.

[54]  Jun Hee Lee,et al.  Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression , 2010, Cell.

[55]  M. Yuen,et al.  Hepatitis B and C virus-related carcinogenesis. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[56]  Y. Hirata,et al.  Hepatitis C Virus Impairs p53 via Persistent Overexpression of 3β-Hydroxysterol Δ24-Reductase* , 2009, The Journal of Biological Chemistry.

[57]  Stephanie Roessler,et al.  MicroRNA expression, survival, and response to interferon in liver cancer. , 2009, The New England journal of medicine.

[58]  I. Ng,et al.  Liver cancer stem cells: implications for a new therapeutic target , 2009, Liver international : official journal of the International Association for the Study of the Liver.

[59]  B. Cieply,et al.  Unique phenotype of hepatocellular cancers with exon‐3 mutations in beta‐catenin gene , 2009, Hepatology.

[60]  X. Wang,et al.  EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. , 2009, Gastroenterology.

[61]  S. Byers,et al.  Liver stem cells and hepatocellular carcinoma , 2009, Hepatology.

[62]  S. Paggi,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[63]  P. van Damme,et al.  The global impact of vaccination against hepatitis B: a historical overview. , 2008, Vaccine.

[64]  S. Yeh,et al.  Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. , 2008, Gastroenterology.

[65]  J. Olynyk,et al.  C-kit inhibition by imatinib mesylate attenuates progenitor cell expansion and inhibits liver tumor formation in mice. , 2008, Gastroenterology.

[66]  Ohad Parnes,et al.  Inflammation , 2008, The Lancet.

[67]  K. Chan,et al.  Aldehyde Dehydrogenase Discriminates the CD133 Liver Cancer Stem Cell Populations , 2008, Molecular Cancer Research.

[68]  S. Sell,et al.  Liver cancer stem cells. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Liang Tang,et al.  Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. , 2008, Cancer research.

[70]  S. Yeh,et al.  Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor , 2008, Hepatology.

[71]  S. Fan,et al.  Identification of local and circulating cancer stem cells in human liver cancer , 2008, Hepatology.

[72]  C. Deng,et al.  Progenitor/stem cells give rise to liver cancer due to aberrant TGF-β and IL-6 signaling , 2008, Proceedings of the National Academy of Sciences.

[73]  Viraj J. Jasinghe,et al.  Inhibition of CD44 expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitivity, and reduces tumorigenesis and invasion , 2008, Cancer Chemotherapy and Pharmacology.

[74]  S. Fan,et al.  Significance of CD90+ cancer stem cells in human liver cancer. , 2008, Cancer cell.

[75]  C. Trautwein,et al.  Is interleukin‐6 a gender‐specific risk factor for liver cancer? , 2007, Hepatology.

[76]  Jin Ding,et al.  From cell signaling to cancer therapy , 2007, Acta Pharmacologica Sinica.

[77]  S. Thorgeirsson,et al.  RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis. , 2007, Gastroenterology.

[78]  Ali H. Brivanlou,et al.  Signaling Pathways in Cancer and Embryonic Stem Cells , 2007, Stem Cell Reviews.

[79]  I. Ng,et al.  Identification and characterization of tumorigenic liver cancer stem/progenitor cells. , 2007, Gastroenterology.

[80]  C. Harris,et al.  TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer , 2007, Oncogene.

[81]  Hongyang Wang,et al.  Use of adenovirus-delivered siRNA to target oncoprotein p28GANK in hepatocellular carcinoma. , 2007, Gastroenterology.

[82]  Jingxia Li,et al.  Cyclooxygenase-2 Induction by Arsenite Is through a Nuclear Factor of Activated T-cell-dependent Pathway and Plays an Antiapoptotic Role in Beas-2B Cells* , 2006, Journal of Biological Chemistry.

[83]  S. Thorgeirsson,et al.  A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells , 2006, Nature Medicine.

[84]  Chuanshu Huang,et al.  Inflammation, a Key Event in Cancer Development , 2006, Molecular Cancer Research.

[85]  Tong Wu,et al.  Cyclooxygenase-2 in hepatocellular carcinoma. , 2006, Cancer treatment reviews.

[86]  E. Hurt,et al.  The role of IL-6 and STAT3 in inflammation and cancer. , 2005, European journal of cancer.

[87]  Tomoko Masuda,et al.  The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. , 2005, Cancer cell.

[88]  Michael Karin,et al.  IKKβ Couples Hepatocyte Death to Cytokine-Driven Compensatory Proliferation that Promotes Chemical Hepatocarcinogenesis , 2005, Cell.

[89]  Hongyang Wang,et al.  Use of Adenovirus-Delivered siRNA to Target Oncoprotein p28GANK in Hepatocellular Carcinoma , 2005 .

[90]  W. Cacheux,et al.  Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis , 2005, Hepatology.

[91]  Jian Yu,et al.  Large-scale cDNA transfection screening for genes related to cancer development and progression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[92]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[93]  N. Fausto.  Liver regeneration and repair: Hepatocytes, progenitor cells, and stem cells , 2004, Hepatology.

[94]  R. Jordan,et al.  Molecular viral oncology of hepatocellular carcinoma , 2003, Oncogene.

[95]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[96]  M. Tai,et al.  Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma , 2003, Cancer.

[97]  Rei Takahashi,et al.  Disruption of the p16/Cyclin D1/Retinoblastoma Protein Pathway in the Majority of Human Hepatocellular Carcinomas , 2001, Oncology.

[98]  J. Jang,et al.  Cyclin D1 overexpression in hepatocellular carcinoma. , 2001, Liver.

[99]  Y. Jeng,et al.  Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. , 2000, The American journal of pathology.

[100]  S. Hirohashi,et al.  Inactivation of p16INK4 in hepatocellular carcinoma , 1996, Hepatology.

[101]  G. Baffy,et al.  Editorial: Hepatocellular Carcinoma in Type 2 Diabetes: More Than Meets the Eye , 2012, The American Journal of Gastroenterology.

[102]  Jin Ding,et al.  Molecular Signaling in Hepatocellular Carcinoma , 2010 .

[103]  C. la Vecchia,et al.  The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[104]  G. Bray,et al.  Obesity , 2008, Annals of Internal Medicine.

[105]  Jingxia Li,et al.  The COX-2 Induction by Arsenite is Through NFAT-Dependent Pathway And Plays Anti-apoptotic Role in Beas-2B cell* , 2006 .

[106]  Rinat Abramovitch,et al.  NF-kappaB functions as a tumour promoter in inflammation-associated cancer. , 2004, Nature.

[107]  이기용.  백미의 acetylcholinesterase 저해 활성 성분 , 2001 .

[108]  Katsuhiko Itoh,et al.  Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas , 2000, Nature Medicine.

[109]  J. Ashby,et al.  Synthesis of 1,6-diaminopyrene from 1,6-dinitropyrene and its S9 dependent mutagenicity to S. typhimurium. , 1983, Carcinogenesis.

[110]  Michael Karin,et al.  References and Notes Supporting Online Material Materials and Methods Som Text Figs. S1 to S6 Tables S1 to S4 Gender Disparity in Liver Cancer Due to Sex Differences in Myd88-dependent Il-6 Production , 2022 .